Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …

Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen
receptors (CARs) have shown remarkable clinical responses and are commercially …

B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies
have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non …

Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-
cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …

The application of chimeric antigen receptor (CAR) T-cell therapy as a tumor immunotherapy
has received great interest in recent years. This therapeutic approach has been used to treat …

Bispecific chimeric antigen receptor T-cell (CAR-T) therapies have shown promising results
in clinical trials for advanced B-cell malignancies. However, it is challenging to broaden the …